REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Skin Repair Stack

Skin & Hairbeginner

84

synergy

84
Share
Peptides

2

Avg Daily mcg

750

Level

beginner

Added

May 17, 2026

Overview

The Skin Repair Stack is a focused two-peptide protocol for accelerating skin healing, collagen production, and tissue recovery following damage from procedures, injuries, or chronic conditions. GHK-Cu is arguably the most well-validated peptide for dermatological applications. Its mechanisms in skin include: stimulation of collagen type I and III synthesis (the primary structural proteins of the dermis), promotion of glycosaminoglycan production (hyaluronic acid, dermatan sulfate) for hydration and plumpness, upregulation of integrin expression for cell adhesion and tissue organization, and attraction of macrophages for debris clearance and growth factor secretion. Clinical studies have demonstrated that GHK-Cu-containing products increase skin thickness, reduce fine lines, and improve elasticity within 12 weeks of consistent use. BPC-157 complements GHK-Cu through its unique vascular and growth factor effects. Skin healing requires robust blood supply for nutrient delivery and waste removal, and BPC-157''s documented promotion of angiogenesis (via VEGF upregulation) ensures adequate perfusion of healing tissue. It also modulates multiple growth factors simultaneously — EGF, FGF, and HGF — creating an environment that accelerates all phases of wound healing: inflammation, proliferation, and remodeling. Animal studies demonstrate that BPC-157 treated wounds show earlier collagen deposition, faster re-epithelialization, and improved tensile strength compared to controls. The combination is particularly effective for post-procedure recovery (after laser treatments, chemical peels, microneedling, or surgery), scar remodeling, chronic wound healing, and general skin rejuvenation in aging skin. GHK-Cu provides the building blocks and instructions for tissue reconstruction, while BPC-157 ensures the infrastructure (blood supply) and growth factor environment support rapid, high-quality repair. The beginner classification reflects the simplicity of the two-compound protocol, the extensive safety literature on both peptides, and the straightforward dosing schedule. Topical GHK-Cu can be applied directly to target areas for localized effects, while subcutaneous BPC-157 provides systemic support.

Dosing Protocol

GHK-Cu

Every day· topical/subcutaneous

Read more about GHK-Cu →

500 mcg

per dose

BPC-157

Every day· subcutaneous

Read more about BPC-157 →

250 mcg

per dose

Goals & Evidence

Skin repairCollagen synthesisWound healingPost-procedure recoveryScar reduction
Evidence tier:Human Data

Warnings

  • BPC-157 is FDA Category 2 — reclassification pending May 2026.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.